Review
doi: 10.1007/s40123-020-00257-7. Epub 2020 May 7.Therapies Based on Nanoparticles for Eye Drug Delivery
Affiliations
- PMID:32383107
- PMCID: PMC7406616
- DOI: 10.1007/s40123-020-00257-7
Item in Clipboard
Review
Therapies Based on Nanoparticles for Eye Drug Delivery
Alejandra Meza-Rios et al. Ophthalmol Ther.2020 Sep.
Display options
Format
Display options
Format
Abstract
Eye drug delivery, particularly to the retina, is a technical hurdle that needs to be solved and represents an ongoing current important medical field. Posterior segment eye diseases are a major cause of visual impairment worldwide. Age-related macular degeneration, glaucoma, and diabetic retinopathy are the major causes of blindness. To achieve efficient drug delivery and drug retention time in the posterior segment of the eye, novel delivery systems based on nanoparticles have been developed in the last few years. Nowadays, liposomes represent the most utilized nanoparticles for eye drug delivery and, recently, a broad spectrum of diverse nanoparticles continue to emerge with special characteristics representing ideal candidates for eye drug delivery.
Keywords: Biotechnology; Eye diseases; Liposomes; Nanoparticles; Posterior segment eye.
Figures
Eye structures and routes of drug administration. Structurally, the eye is composed of an internal compartment which consists of the anterior and posterior chambers—the iris, lens, vitreous cavity, retina, ciliary body, the choroid, and intrinsic ocular muscles—and an external compartment—which consists of the conjunctiva, the cornea, the sclera, and the tear film. There are different routes for eye drug administration likea intravitreal injection;b topical;c periocular injections; andd systemic administration
Materials in nanomedicine for eye drug delivery. Specific nanomolecules have been developed and/or applied as carriers for eye drug delivery. Representative structures of the principal nanoparticles are presented in this figure
Similar articles
- Posterior Segment Ophthalmic Drug Delivery: Role of Muco-Adhesion with a Special Focus on Chitosan.Burhan AM, Klahan B, Cummins W, Andrés-Guerrero V, Byrne ME, O'Reilly NJ, Chauhan A, Fitzhenry L, Hughes H.Burhan AM, et al.Pharmaceutics. 2021 Oct 14;13(10):1685. doi: 10.3390/pharmaceutics13101685.Pharmaceutics. 2021.PMID:34683978Free PMC article.Review.
- Nanomedicine and drug delivery to the retina: current status and implications for gene therapy.Tawfik M, Chen F, Goldberg JL, Sabel BA.Tawfik M, et al.Naunyn Schmiedebergs Arch Pharmacol. 2022 Dec;395(12):1477-1507. doi: 10.1007/s00210-022-02287-3. Epub 2022 Sep 15.Naunyn Schmiedebergs Arch Pharmacol. 2022.PMID:36107200Free PMC article.Review.
- Modern drug delivery systems for targeting the posterior segment of the eye.Peptu CA, Popa M, Savin C, Popa RF, Ochiuz L.Peptu CA, et al.Curr Pharm Des. 2015;21(42):6055-69. doi: 10.2174/1381612821666151027151847.Curr Pharm Des. 2015.PMID:26503152Review.
- Delivery of therapeutics for deep-seated ocular conditions - status quo.Nguyen H, Eng S, Ngo T, Dass CR.Nguyen H, et al.J Pharm Pharmacol. 2018 Aug;70(8):994-1001. doi: 10.1111/jphp.12924. Epub 2018 Apr 19.J Pharm Pharmacol. 2018.PMID:29675844Review.
- Drug delivery to the posterior segment of the eye.Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG.Thrimawithana TR, et al.Drug Discov Today. 2011 Mar;16(5-6):270-7. doi: 10.1016/j.drudis.2010.12.004. Epub 2010 Dec 15.Drug Discov Today. 2011.PMID:21167306Review.
Cited by
- Microfluidic Fabricated Liposomes for Nutlin-3a Ocular Delivery as Potential Candidate for Proliferative Vitreoretinal Diseases Treatment.Esposito E, Pozza E, Contado C, Pula W, Bortolini O, Ragno D, Toldo S, Casciano F, Bondi A, Zauli E, Secchiero P, Zauli G, Melloni E.Esposito E, et al.Int J Nanomedicine. 2024 Apr 11;19:3513-3536. doi: 10.2147/IJN.S452134. eCollection 2024.Int J Nanomedicine. 2024.PMID:38623081Free PMC article.
- Understanding the role of biomolecular coronas in human exposure to nanomaterials.Soliman MG, Martinez-Serra A, Antonello G, Dobricic M, Wilkins T, Serchi T, Fenoglio I, Monopoli MP.Soliman MG, et al.Environ Sci Nano. 2024 Sep 9;11(11):4421-4448. doi: 10.1039/d4en00488d. eCollection 2024 Nov 7.Environ Sci Nano. 2024.PMID:39263008Free PMC article.Review.
- Gene Therapy for Rhodopsin Mutations.Lewin AS, Smith WC.Lewin AS, et al.Cold Spring Harb Perspect Med. 2022 Aug 8;12(9):a041283. doi: 10.1101/cshperspect.a041283. Online ahead of print.Cold Spring Harb Perspect Med. 2022.PMID:35940643Free PMC article.
- Contact Lenses as Ophthalmic Drug Delivery Systems: A Review.Franco P, De Marco I.Franco P, et al.Polymers (Basel). 2021 Mar 30;13(7):1102. doi: 10.3390/polym13071102.Polymers (Basel). 2021.PMID:33808363Free PMC article.Review.
- Moxifloxacin Liposomes: Effect of Liposome Preparation Method on Physicochemical Properties and Antimicrobial Activity againstStaphylococcus epidermidis.Natsaridis E, Gkartziou F, Mourtas S, Stuart MCA, Kolonitsiou F, Klepetsanis P, Spiliopoulou I, Antimisiaris SG.Natsaridis E, et al.Pharmaceutics. 2022 Feb 7;14(2):370. doi: 10.3390/pharmaceutics14020370.Pharmaceutics. 2022.PMID:35214102Free PMC article.
References
- Pascolini D, Mariotti SP. Global estimates of visual impairment: 2010. Br J Ophthalmol. 2012;96:614–618. - PubMed
- Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. Lancet Glob Health. 2017;5:e1221–e1234. - PubMed
- Tan GS, Cheung N, Simó R, Cheung GC, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017;5:143–155. - PubMed
- Grzybowski A, Told R, Sacu S, et al. 2018 Update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica. 2018;239:181–193. - PubMed
Publication types
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources